Hjem › Seglcelle-anæmi › Illinois
Seglcelle-anæmi kliniske forsøg i Illinois
19 studier for Seglcelle-anæmi søger deltagere på steder i Illinois.
Byer i Illinois
Officiel studietekst (engelsk)
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
- University of Illinois at Chicago College of Medicine, Chicago
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT04055818A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- Uni of Illinois Hospital and HSC, Chicago
RekruttererFase 3
Alder 12 til 100 · Alle køn · Opdateret 28. sep. 2026 · NCT06439082A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
- University of Illinois Hospital and Health Sciences System, Chicago
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT07187973A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Univer Of Illinois at Chicago, Chicago
RekruttererFase 3
Alder 2 og opefter · Alle køn · Opdateret 18. sep. 2026 · NCT06609226A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Childrens Hospital of Chicago, Chicago
- Univer Of Illinois at Chicago, Chicago
RekruttererFase 3
Alder 12 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT06612268Tocilizumab for Acute Chest Syndrome
- University of Chicago, Chicago
RekruttererFase 2
Alder 12 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT05640271A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
- Local Institution - 0034, Chicago
RekruttererFase 1/2Frivillige med god helbredstilstand velkomne
Alder 18 og opefter · Alle køn · Opdateret 18. aug. 2026 · NCT06481306A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- University of Illinois at Chicago Clinical Research Center, Chicago
- University of Illinois Hospital and Health Sciences System - Investigational Drug Services (IDS), Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
RekruttererFase 2/3
Alder 12 og opefter · Alle køn · Opdateret 18. aug. 2026 · NCT05431088ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Rush University Medical Center, Chicago
- Bleeding and Clotting Disorders Institute, Peoria
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 17. aug. 2026 · NCT04398628Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- University of Illinois at Chicago, Chicago
RekruttererFase 2
Alder 12 og opefter · Alle køn · Opdateret 14. aug. 2026 · NCT06699849The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- University of Illinois-Chicago - College of Medicine- Site Number : 8400054, Chicago
RekruttererFase 3
Alder 10 til 65 · Alle køn · Opdateret 29. jul. 2026 · NCT06975865Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
- University of Illinois at Chicago, Chicago
RekruttererFase 2
Alder 16 til 60 · Alle køn · Opdateret 8. jul. 2026 · NCT03121001Sickle Cell Clinical Research and Intervention Program
- Children's Hospital of Illinois at OSF-Saint Francis Medical Center, Peoria
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 4. jun. 2026 · NCT02098863Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
- Comer Children's Hospital (MRD-HCT), Chicago
RekruttererObservationsstudie
Alder 3 til 20 · Alle køn · Opdateret 4. jun. 2026 · NCT06941389Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
- University of Illinois Chicago, Sickle Cell Center, Chicago
RekruttererFase 2
Alder 18 til 60 · Alle køn · Opdateret 19. maj 2026 · NCT07175051Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
- University of Illinois at Chicago, Chicago
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 23. mar. 2026 · NCT06919224Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RekruttererFase 2
Alder 2 til 25 · Alle køn · Opdateret 10. mar. 2026 · NCT03587272Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
- Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago
Rekrutterer
Alder 16 til 30 · Alle køn · Opdateret 7. jan. 2026 · NCT06374238Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
- University of Illinois, Chicago
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 22. jun. 2025 · NCT06385886Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.